

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia (a double blind, placebo controlled, randomized trial)

Protocol summary

Summary

The object of this randomized, placebo controlled, double blind study is to test the hypothesis that the addition of Buspirone would improve psychopathology in subjects with Schizophrenia treated with Typical Antipsychotics. 50 patients with ages between 18-65 years who have no other medical or psychiatric conditions with chronic DSMIV-TR diagnosed Schizophrenia will receive Typical Antipsychotics combined with either placebo (N=25) or 30 mg/day of Buspirone (N=25) for 6 weeks. Efficacy will be defined as the change from baseline to endpoint in score on the Positive and Negative Syndrome Scale(PANSS). Side effects will be also evaluated using checklist and Extrapyramidal Symptom Rating Scale. PANSS, SAS, GAF, MMSE Scales and side effects will be evaluated at baseline, 2, 4 and 6 weeks.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201106026691N1**
Registration date: **2012-09-17, 1391/06/27**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-09-17, 1391/06/27

Registrant information

Name

Fatemeh Sheikhmoonesi

Name of organization / entity

Mazandaran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 15 1328 5109

Email address

fmoonesi@mazums.ac.ir

Recruitment status

Recruitment complete

Funding source

Mazandaran University of Medical Sciences and Health Service

Expected recruitment start date

2012-04-03, 1391/01/15

Expected recruitment end date

2012-11-21, 1391/09/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia (a double blind, placebo controlled, randomized trial)

Public title

Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Age between 18-65; Diagnosis of Schizophrenia based on DSMIV-TR; Chronic Schizophrenia (over 2 years); Ongoing treatment with Typical Antipsychotics. Exclusion criteria: Allergic to Buspirone; Any chronic medical problem; Substance dependency; Any other Psychiatric Disorder in Axis I or II; Pregnancy or Breast feeding.

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Mazandaran University of Medical Sciences

Street address

Central building of Mazandaran University of Medical Sciences and Health Service, Daneshgah Blvd, Emam Square

City

Sari

Postal code

48154

Approval date

2011-05-31, 1390/03/10

Ethics committee reference number

1353

Health conditions studied

1

Description of health condition studied

Schizophrenia

ICD-10 code

F20

ICD-10 code description

Schizophrenia

Primary outcomes

1

Description

Severity of schizophrenia

Timepoint

Baseline and weeks 2-4-6 after beginning of treatment

Method of measurement

Positive and Negative Syndrome Scale(PANSS)

Secondary outcomes

1

Description

Headache

Timepoint

Baseline and weeks 2,4,6 after beginning of treatment

Method of measurement

Check list of adverse effects

2

Description

Nausea

Timepoint

Baseline and weeks 2-4-6 after beginning of treatment

Method of measurement

Checklist of adverse effects

3

Description

Palpitation

Timepoint

Baseline and weeks 2-4-6 after beginning of treatment

Method of measurement

Checklist of adverse effects

Intervention groups

1

Description

Typical Antipsychotics combined with Tablet Bupirone(30 mg/day) as intervention group for 6 weeks

Category

Treatment - Drugs

2

Description

Typical Antipsychotics combined with Tablets placebo as control group for 6 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Zare Psychiatry Hospital
Full name of responsible person
Dr Fatemeh Sheikhmoonesi
Street address
Psychiatric Department, Zare Psychiatry Hospital, Sari
City
Sari

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Ahmadali Enayati
Street address
Vice Chancellor for Research and Technology,
Building N.2, Moallem Square, Moallem Street
City
Sari

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Mazandaran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Fatemeh Sheikhmoonesi
Position
Assistant Prof. of Psychiatry, Psychiatrist
Other areas of specialty/work
Street address
Zare Psychiatry Hospital
City
Sari
Postal code
4815466848
Phone
+98 15 1328 5109
Fax
+98 15 1328 5109
Email

fmoonesi@mazums.ac.ir
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Fatemeh Sheikhmoonesi
Position
Assistant Prof. of Psychiatry, Psychiatrist
Other areas of specialty/work
Street address
Zare Psychiatry Hospital
City
Sari
Postal code
4815466848
Phone
+98 15 1328 5109
Fax
+98 15 1328 5109
Email
fmoonesi@mazums.ac.ir
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Fatemeh Sheikhmoonesi
Position
Assistant Prof. of Psychiatry, Psychiatrist
Other areas of specialty/work
Street address
Zare Psychiatry Hospital
City
Sari
Postal code
4815466848
Phone
+98 15 1328 5109
Fax
+98 15 1328 5109
Email
fmoonesi@mazums.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty